Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553772 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT02553772 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 242 participants.
The verdict
NCT02553772, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.
Interventions
- DRUG Carboxymethylcellulose Based Eye Drop
- DRUG Carboxymethylcellulose Sodium 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2016-09-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553772
The ClinicalTrials.gov registry entry for NCT02553772 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboxymethylcellulose Based Eye Drop is the first listed.
NCT02553772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553772 about?
NCT02553772 is a clinical study titled "A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.". This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.
What is the current status of trial NCT02553772?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2016-01-06. Estimated completion is 2016-09-09.
What interventions are being tested in trial NCT02553772?
The interventions under investigation include: Carboxymethylcellulose Based Eye Drop (DRUG), Carboxymethylcellulose Sodium 0.5% (DRUG).
Who is sponsoring clinical trial NCT02553772?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.